Veru (VERU)
(Delayed Data from NSDQ)
$1.27 USD
+0.06 (4.96%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.27 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Veru Inc. [VERU]
Reports for Purchase
Showing records 61 - 80 ( 92 total )
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Phase 2 Trial Doses First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 1Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2 Hot Flashes Study Reports Positive Data; Reiterate Buy; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 4Q and Full-Year 2019 Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2 Hot Flashes Study Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 3Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
TADFIN 505(b)(2) NDA Submission Requirements Clarified; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Prostate Cancer Pipeline Strengthened with New Biologic Candidate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal 2Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Fiscal 1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Phase 1b/2 Prostate Cancer Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Tad-Fin Combo Tablet Delivers Positive Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
FY2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Medical - Products
Financing Completed; Hot Flashes Trial Enrollment Starts; Reiterate Buy and Lowering Price Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
Positive Pre-IND Meeting for VERU-111 in Prostate Cancer; Phase 1/2 Study Starts Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
South Africa Tender First Year Revenue Reaches $10.4M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
South Africa Female Condom Tender Awarded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
3Q FY2018 Results Reported; Anticipating South Africa Tender and Clinical Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Veru Inc.
Industry: Cosmetics
We are initiating coverage on VERU shares with a BUY rating and 12-18-month price target of $5.00.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Veru Inc.
Industry: Cosmetics
VERU-944 Phase 2 Trial to Start in Summer; Patent Issued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R